Article Details

GSK to Acquire Affinivax for Up to $3.3B, Bolstering Vaccine Portfolio

Retrieved on: 2022-05-31 16:09:42

Tags for this article:

Click the tags to see associated articles and topics

GSK to Acquire Affinivax for Up to $3.3B, Bolstering Vaccine Portfolio. View article details on hiswai:

Excerpt

GSK is counting on Affinivax to help it compete better with Pfizer's blockbuster pneumococcal vaccine franchise, marketed as Prevnar®, ...

Article found on: www.genengnews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up